Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Northwestern University
Deal Size : Inapplicable
Deal Type : Inapplicable
Nanopharmaceutics and Northwestern Start Phase I Study of Oral Triapine® for Glioblastoma
Details : Oral Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) in combination with temozolomide is being evaluated in the early-stage trial for recurrent glioblastoma.
Product Name : Triapine
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 14, 2024
Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Northwestern University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Cisplatin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer.
Product Name : Triapine
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2022
Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable